These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36328291)

  • 1. Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study.
    Lakatos B; Szabó BG; Bobek I; Kiss-Dala N; Gáspár Z; Riczu A; Petrik B; Farkas BF; Sebestyén G; Gopcsa L; Bekő G; Sinkó J; Reményi P; Szlávik J; Mathiász D; Vályi-Nagy I
    Int J Infect Dis; 2022 Dec; 125():233-240. PubMed ID: 36328291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.
    Gáspár Z; Szabó BG; Andrikovics H; Ceglédi A; Rajmon M; Ábrahám A; Várnai Z; Kiss-Dala N; Szlávik J; Sinkó J; Vályi-Nagy I; Lakatos B
    Geroscience; 2024 Jun; 46(3):2863-2877. PubMed ID: 38367195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
    Troyer BS; Kovacic Scherrer N; Garavaglia J
    J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
    Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
    Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19.
    Peterson JH; Paranjape NS; Grundlingh N; Priestley JL
    Crit Care Med; 2023 Mar; 51(3):337-346. PubMed ID: 36729439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
    Reid NK; Joyner KR; Lewis-Wolfson TD
    Ann Pharmacother; 2023 Jul; 57(7):769-775. PubMed ID: 36314277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.
    Karolyi M; Gruebl A; Omid S; Saak M; Pawelka E; Hoepler W; Kelani H; Kuran A; Laferl H; Ott C; Pereyra D; Santol J; Seitz T; Traugott M; Assinger A; Wenisch C; Zoufaly A
    Infection; 2023 Aug; 51(4):851-858. PubMed ID: 36083403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study.
    Szabó BG; Czél E; Nagy I; Korózs D; Petrik B; Marosi B; Gáspár Z; Rajmon M; Di Giovanni M; Vályi-Nagy I; Sinkó J; Lakatos B; Bobek I
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
    Sarhan NM; Warda AEA; Ibrahim HSG; Schaalan MF; Fathy SM
    Sci Rep; 2023 Apr; 13(1):6456. PubMed ID: 37081046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
    Walker CP; Hurlock NP; Deb S
    Diseases; 2024 May; 12(5):. PubMed ID: 38785762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.